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Two-component mRNA vaccines (RNActive®) combine
high antigen expression with strong immune stimulation.
Intradermal injections of RNActive® vaccines induced
balanced, potent and long-lasting immune responses
which can be boosted via repetitive vaccinations.
Although the strong immune response induced by
RNActive® vaccination alone already led to a potent thera-
peutic anti-tumor response in the E.G7-Ovalbumin tumor
model, the combination of RNActive® vaccination with
radiation or checkpoint inhibitors elicited strong synergis-
tic effects, resulting in an even more effective anti-tumor
response.
Monotherapy with either OVA-RNActive® or radiation
was not effective in curing mice bearing large E.G7-OVA
tumors. Also, high dose radiation of tumors induced only
transient growth stagnation. In contrast, the combination
of RNActive® vaccination and radiation dramatically
improved anti-tumor efficacy and supported surveillance
of large tumors in the treated mice.
Combinatorial treatment of mice bearing already estab-
lished E.G7-OVA tumors with OVA- RNActive® and
checkpoint inhibitors such as anti-CTLA-4 or anti-PD-1
monoclonal antibody resulted in a strong, synergistic anti-
tumor effect, yielding a higher frequency of mice with
complete tumor rejection compared to treatment with the
single components. Remarkably, these complete respon-
ders were protected against re-challenge with parental
ovalbumin-negative EL-4 tumors, indicating antigen
spreading in these groups.
The safety and immunogenicity of RNActive® vaccines
have been already successfully tested in humans in two
cancer indications: non-small cell lung cancer (CV9201)
and prostate cancer (CV9103). Data from both trials
revealed induction of the immune responses against all
antigens included in the vaccination protocol.
In conclusion, our results demonstrate that intrader-
mal vaccinations with self-adjuvanting RNActive®
induce potent anti-tumor immune responses which can
be further enhanced by combination with other thera-
pies such as checkpoint inhibitors or radiation. Thus,
RNActive® vaccines constitute an attractive vaccination
platform for combination therapies in the field of cancer
immunotherapy.
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